#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Nephrotic syndrome Cluster headache Follicular lymphoma stage III Encephalitis autoimmune Microscopic polyangiitis Fatty acid oxidation disorder Dupuytren's contracture Castleman's disease Polyneuropathy Langerhans' cell histiocytosis Infertility male Oesophageal achalasia Vaginal cancer Fibrosarcoma Osteosarcoma metastatic More trials…

    Learn about Rare Diseases

    Hereditary neuropathic amyloidosis Pelizaeus-Merzbacher disease – Trials in Disease Soft tissue sarcoma – Diagnostics Mucopolysaccharidosis III – Treatment Advanced systemic mastocytosis – Trials in Disease Mantle cell lymphoma refractory Hereditary angioedema – Life with Disease Hypereosinophilic syndrome – Trials in Disease Biotinidase deficiency – Diagnostics Glycogen storage disease type II More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sotrovimab Metronidazole Corline Heparin Conjugate 11902A DUVELISIB Colistin Sulfate HEMOPEXIN, HUMAN Bintrafusp Alfa Cabotegravir Timothy Grass Pollen Extract ADX-324 Imlifidase Lanreotide Clarithromycin Ciprofloxacin Hydrochloride Gadobutrol Lurasidone Midodrine Hydrochloride Int-787 Zinc Oxide More therapies…

    Learn about Your Condition

    Toxicity to various agents Prader-Willi syndrome Vulvovaginal dryness Eclampsia Dermatitis atopic Chondrosarcoma metastatic Hypereosinophilic syndrome Breast cancer female Bacterial infection Meningioma malignant Coma Tuberculosis Salivary gland cancer Scoliosis Renal cancer recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Relapsing-remitting multiple sclerosis

  • Study on Anti-CD20 Therapy and Drug Combination for Patients with Relapsing-Remitting Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Relapsing-remitting multiple sclerosis
    Investigated Drugs:
    • Dimethyl Fumarate
    • Diroximel Fumarate
    • Glatiramer Acetate
    France

  • Study Comparing the Effects of Ozanimod and Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Ozanimod Hydrochloride
    • Fingolimod
    Italy Poland Portugal Romania Spain

  • Study on the Effects of Ozanimod on Inflammation in Patients with Relapsing Multiple Sclerosis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Progressive relapsing multiple sclerosis
    • Relapsing-remitting multiple sclerosis
    • Multiple sclerosis
    Investigated Drugs:
    • Ozanimod
    Italy

  • Study on the Effects of IMU-838 (Vidofludimus Calcium) for Patients with Relapsing-Remitting Multiple Sclerosis

    Recruiting

    2 1
    Investigated Drugs:
    • Vidofludimus Calcium
    Bulgaria Germany Poland Romania

  • Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous Ocrelizumab in Children and Adolescents with Relapsing‑Remitting Multiple Sclerosis

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Ocrelizumab
    France Germany Poland

  • Study of Lactobacillales and Lacidofil in Multiple Sclerosis Patients: Comparing Effectiveness of Probiotic Therapy

    Not yet recruiting

    2 1 1 1 1
    Investigated Diseases:
    • Relapsing-remitting multiple sclerosis
    • Multiple sclerosis
    Investigated Drugs:
    • Lactobacillus Rhamnosus, Strain Lcr35, Live
    • Ozanimod
    • Ofatumumab
    Poland
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!